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Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is common, affecting nearly 400 million people worldwide. Achieving
good health for people with T2DM requires active self-management; however, uptake of self-management education
is poor, and there is an urgent need to find better, more acceptable, cost-effective methods of providing self-
management support. Web-based self-management support has many potential benefits for patients and health
services. The aim of this trial is to determine the effectiveness and cost-effectiveness of a web-based self-management
support programme for people with T2DM.
Methods: This will be a multi-centre individually randomised controlled trial in primary care, recruiting adults with
T2DM who are registered with participating general practices in England. Participants will be randomised to receive
either an evidence-based, theoretically informed, web-based self-management programme for people with T2DM
which addresses medical, emotional, and role management, called Healthy Living for People with type 2 Diabetes
(HeLP-Diabetes) or a simple information website. The joint primary outcomes are glycated haemoglobin (HbA1c) and
diabetes-related distress, measured by the Problem Areas In Diabetes (PAID) questionnaire. Secondary outcomes
include cardiovascular risk factors, depression and anxiety, and self-efficacy for self-management of diabetes. Health
economic data include health service use, costs due to the intervention, and EQ-5D for calculation of Quality Adjusted
Life Years (QALYS). Data will be collected at baseline, 3 months and 12 months, with the primary endpoint at
12 months. Practice nurses, blinded to patient allocation, collect clinical data; patients complete online questionnaires
for patient reported measures. A sample size of 350 recruited participants allows for attrition of up to 15 % and will
provide 90 % power of detecting at a 5 % significance level a true average difference in the PAID score of 4.0 and
0.25 % change in HbA1c (both small effect sizes). The analysis will follow a pre-specified analysis plan, based on
comparing the groups as randomised (intention-to-treat).
Discussion: The findings of this trial are likely to be of interest to policy makers, clinicians, and commissioners, all of
whom are actively seeking additional forms of self-management support for people with T2DM.
Trial registration: The Trial Registration number is ISRCTN 02123133; date of registration 14.2.13.
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Background
Type 2 diabetes (T2DM) is one of the commonest long
term conditions affecting nearly 400 million people
worldwide [1] and over 3 million in the UK [2]. T2DM
can cause severe complications including cardiovascular
disease, blindness, renal failure and neuropathy, and can
reduce life expectancy by 8 – 10 years [3]. In the UK,
approximately 12 % of deaths of people between the ages
of 20 – 79 years are attributable to diabetes and about
10 % of the NHS budget (£9 billion per annum) is spent
on diabetes [4]. Many of these costs are due to prevent-
able complications. The key to good clinical outcomes in
people with diabetes is self-management which can reduce
both the incidence and impact of complications. Struc-
tured education is known to promote self-management
and reduce the incidence of diabetes complications [5–7].
In 2008, the National Institute for Health and Care
Excellence (NICE) advised that all patients with diabetes
should be offered structured education at the time of diag-
nosis with annual reinforcement [3]. NICE advised that
such structured education or self-management pro-
grammes (SMP) should improve outcomes through ad-
dressing health beliefs, optimising metabolic control,
addressing cardiovascular risk factors, facilitating behav-
iour change, improving quality of life and reducing de-
pression as well as enhancing the relationship between the
patient and their healthcare professionals [3].
Examples of existing self-management programmes for
people with type 2 diabetes in the UK include DES-
MOND [7], X-PERT [8] and Co-Creating Health [9]. Al-
though these programmes have shown initial benefits,
there are concerns that benefits may not be sustained in
the long term [10]. There are additional concerns that
group-based programmes such as these may not suit all
patients who need self-management training. People
who work, have caring responsibilities at home, have
mobility problems, or who find group interactions diffi-
cult may all have difficulty attending. Thus there is an
urgent need to find cost-effective and acceptable
methods of delivering sustainable self-management edu-
cation for people with type 2 diabetes in the UK. One
possibility is the use of web-based or computer-based
self-management programmes. These have many poten-
tial advantages, including convenience, accessibility and
anonymity. For people with home access to the internet
(84 % of UK households in 2014) [11], such programmes
can be accessed at any time of day or night so can be fit-
ted in around responsibilities at home or work. Informa-
tion can be presented accessibly using simple graphics
or audio-visual techniques and can be easily updated as
new research becomes available. Programmes can be
highly interactive, responding to data entered by individ-
ual users to provide a tailored, personalised experience.
They can offer structured behaviour change support
including self-assessment, goal-setting, monitoring and
feedback. Users can gain emotional support from read-
ing about others’ experiences with similar problems
(personal stories), participating in online forums, or
using online support tools such as computerised cogni-
tive behavioural therapy or mindfulness training. Unlike
face-to-face interventions, computerised programmes
can be permanently available and provide both on-going
support as well as meeting changing needs as the disease
progresses. The marginal costs per additional user are
low, so such interventions have the potential to be
highly cost-effective. A recent Cochrane systematic re-
view of such programmes suggested they can improve
some health outcomes including glycaemic control,
weight and lipids, but there were insufficient data to
draw any conclusions about their impact on emotional
well-being, quality of life or cost-effectiveness. None of
these programmes addressed all the areas specified by
NICE for self-management education, and none were
developed in the UK [12].
We have developed a web-based self-management
programme for people with type 2 diabetes known as
HeLP-Diabetes, or Healthy Living for People with type 2
diabetes. HeLP-Diabetes was developed as part of a Na-
tional Institute for Health Research (NIHR) Programme
Grant for Applied Research. The content and develop-
ment of HeLP-Diabetes was based on five main principles:
first, we adopted the Corbin and Strauss model of the
work required for self-management of a long-term condi-
tion, which includes medical management (e.g. adopting
healthy behaviours, working with health professionals,
managing medicines), emotional management (e.g. man-
aging the strong negative emotions resulting from being
diagnosed with a long term condition including anger,
guilt, shame and despair), and role management (e.g. man-
aging the disruption of one’s biographical narrative) [13].
This model gave us an overarching framework of patients’
requirements. Secondly we undertook extensive qualita-
tive work with our target users, defined as patients with
type 2 diabetes and health professionals who care for these
patients, to identify user needs and wants from such a
programme. Effective self-management requires a partner-
ship between patients and health professionals so it was
important to ensure that the programme was acceptable
to both groups of users. User input continued throughout
the development process with user panels providing itera-
tive comments on materials as they were developed and
refined (participatory design), ensuring that the final
programme was highly acceptable to both patients and
health professionals. Thirdly, we reviewed the behaviour
change literature to identify behaviour change techniques
that were most likely to be effective in helping patients
achieve sustainable behaviour change. Fourthly, we ap-
plied the principles of Normalization Process Theory
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(NPT) to maximise the likelihood of the programme being
easily implemented and integrated into routine NHS care
[14]. Finally, we ensured that all information provided in
the programme was evidence-based and compatible with
current NICE guidelines.
Methods/design
Aims and objectives
The aims of the trial are to:
1. Determine the effect of HeLP-Diabetes on clinical
outcomes and health related quality of life in people
with T2DM
2. Determine the incremental cost-effectiveness of the
intervention from the perspectives of health and
personal social services and wider public sector
resources.
Hypothesis: that use of the intervention will improve
diabetes-related quality of life and health status.
Design
Multi-centre, two-arm individually randomised controlled
trial in primary care.
Ethics and trial registration
This trial received ethical approval from Camden and Is-
lington Research Ethics Committee reference 12/LO/1571.
The Trial Registration number is ISRCTN 02123133.
Setting
General practices in England.
Participants
Inclusion criteria:
 Adults aged 18 or over, with type 2 diabetes.
Exclusion criteria:
 Unable to provide informed consent e.g. due to
psychosis, dementia or severe learning difficulties
 Terminally ill with less than 12 months life
expectancy
 Unable to use a computer due to severe mental or
physical impairment
 Insufficient mastery of spoken or written English to
use the intervention
Participants do not have to have home internet access
or prior experience of using the internet to participate.
Participants with previous or current experience of self-
management education are eligible to participate.
Recruitment
Approximately 20 practices will be recruited through 5
Primary Care Research Networks (PCRN) in England
(South West Central, East of England, South East,
Greater London) and the North Central London Re-
search Consortium (NoCLOR). Practices will be assessed
for their feasibility (e.g. large enough diabetes register to
be able to invite a minimum of 300 eligible participants;
staff are trained in Good Clinical Practice (GCP); 2 mem-
bers of staff available to carry out the study so that 1 can
support the participant in use of the intervention and the
other can remain blinded for data collection) prior to
agreement to act as a participating site. Once a practice
has agreed to participate and completed site set-up proce-
dures they will commence patient recruitment.
Patient recruitment will follow standard opt-in proce-
dures. Each practice will have a register of patients with
type 2 diabetes as they need this for the Quality and
Outcomes Framework. A nurse or other qualified health
professional will review the electronic medical record of
each of the patients on this register with a view to
screening out ineligible patients. All remaining poten-
tially eligible patients will be sent a letter from their GP,
inviting them to participate in the study. A participant
information sheet, consent form, expression of interest
and stamped addressed envelope will be included. Patients
who are interested in participating will be asked to return
the expression of interest form to the trial manager.
In addition posters advertising the study will be put up
in each practice so that patients can ask a clinician dir-
ectly for more information about taking part.
On receipt of the expression of interest form the nurse
will contact the patient and offer them an appointment at
the practice. At this appointment, patients will be given an
opportunity to discuss the pros and cons of participation,
and those that agree to participate will be asked to sign
the written consent form. After signing the consent form,
participants will be asked to complete baseline data collec-
tion procedures prior to randomisation. Randomisation
marks the point of entry into the trial.
Randomisation
Randomisation will be performed only after all baseline
data collection has been completed. Randomisation will
be at the level of the individual participant. It will be
stratified by recruitment centre and will be performed
centrally using a web-based randomisation system pro-
vided by an independent contractor (Sealed Envelope
http://www.sealedenvelope.com/). This system will send
an email to the trial manager when a patient has been
randomised detailing which arm the patient has been al-
located to. This will then be forwarded to the nurse who
will be introducing the control and intervention websites
to the patients in visit 2.
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Intervention
The intervention consists of facilitated and supported
access to HeLP-Diabetes. There are three components
to the supported access: first an introductory session,
secondly supportive follow-up phone calls, and thirdly,
on-going discussion of patient’s self-management goals
in routine appointments for diabetes-related matters.
In the introductory session practice nurses will give
the patient a booklet containing the uniform resource
locator (URL) for the programme, the participant’s log in
details, and information about the content of the website
and how best to use it. Nurses will show the patient how
to access the website, and introduce them to the main
content areas. The nurse will discuss with the patient
what the patient’s most pressing needs are and use this
to guide the patient toward certain sections (for ex-
ample, improving diet, being more physically active, or
managing emotions). Follow-up phone calls will be of-
fered to support the patient in use of the programme.
Nurses and doctors in participating practices will be en-
couraged to refer to the programme in consultations
with participating patients and to integrate information
from the programme into management plans.
HeLP-Diabetes is a web-based programme with mul-
tiple components. There are information sections in-
cluding how diabetes is treated, possible complications
of diabetes, possible impacts of diabetes on relationships
at home and at work, dealing with unusual situations
like parties, holidays, travelling or shift work, and what
lifestyle modifications will improve health. There are
sections addressing skills and behaviour change, includ-
ing behaviour change modules on eating healthily, losing
weight, being more physically active, smoking cessation,
moderating alcohol consumption, managing medicines,
glycaemic control and blood pressure control. These all
include motivating information on the benefits of behav-
iour change, self-assessment quizzes for patients to as-
sess whether and how much they need to change, and
opportunities for goal-setting and self-monitoring. The
third strand of components focuses on emotional well-
being and contains self-help tools based on cognitive be-
havioural therapy and mindfulness. There are multiple
personal stories (used with license from healthtalk.org),
and a moderated forum for users to interact with each
other.
Comparator
From an NHS perspective the important research ques-
tion is whether the proposed intervention can improve
health outcomes when compared to current practice.
However, to improve acceptability to participants and
help maintain blinding, all participants will have access
to a website. Participants in the control arm will have
access to a simple information website, based on the
information available on the Diabetes UK and NHS
Choices websites. These participants will also be given a
booklet with the URL and user log in details, and will also
have the introductory session with the nurse explaining
how to use the website and offer of follow-up phone calls.
However, as the website will have no behaviour change
components, no emotional support and only simple infor-
mation, it is unlikely that there will be many opportunities
to refer to it in diabetes-related appointments.
Outcomes and outcome measures
Primary outcomes
The outcomes reflect our aims of improving clinical out-
comes and health related quality of life. We have selected
two joint primary outcomes: glycated haemoglobin
(HbA1c) and diabetes-related distress measured by the
Problem Areas in Diabetes (PAID) scale [15]. PAID has 20
items focusing on areas that cause difficulty for people liv-
ing with diabetes, including social situations, food, friends
and family, diabetes treatment, relationships with health
care professionals and social support. It has been the sub-
ject of a number of reviews comparing available quality of
life measures for diabetes. Eigenmann assessed available
measures against criteria of: reliability; content, face, con-
struct, criterion and convergent validity; responsiveness to
change; interpretability; response burden; acceptability;
and availability and concluded that PAID was one of three
measures that met all criteria [16]. It is sensitive to change
and has been widely used to evaluate self-management
programmes for people with T2DM including the influen-
tial DESMOND trial [7].
Secondary outcomes
Secondary outcomes have been selected to reflect the
proposed pathway of action of our intervention and
allow health economic analysis and can be categorised
as clinical, patient-reported, or economic.
Clinical outcomes include:
 Systolic and diastolic blood pressure
 Body mass index;
 Total cholesterol and HDL (not fasting)
 Completion of “9 essential processes” [3] (= weight,
BP, smoking status, measurement of serum
creatinine, cholesterol and HbA1c, urinary albumin
and assessment of eyes and feet).
Patient-reported outcomes:
 Depression and anxiety measured using the Hospital
Anxiety and Depression Scale (HADS) [17]
 Diabetes-related self-efficacy measured using the
Diabetes Management Self-Efficacy Scale (DMSES) [18]
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 Satisfaction with treatment measured using the
Diabetes Satisfaction with Treatment Questionnaire
status and change version (DTSQs & DTSQc) [19].
Economic outcomes:
 Cost of developing the intervention
 Cost of supported access
 Costs of training NHS staff both in using the
intervention and training patients to use the
intervention
 Costs of maintaining and updating the intervention
 Health care and social service utilisation during the
study period
 EQ-5D to calculate QALYs [20]
 Clinical parameters required for modelling long
term cost-effectiveness of the intervention (detailed
below).
In addition we will use automated software to record
each participant’s use of the intervention (number and
frequency of log-ins, pages visited).
Data collection
Data to describe our patient population will be collected
at baseline and will include demographic and clinical data.
Demographic data will include: age, gender, highest
educational attainment, ethnicity, current employment
status, presence or absence of home internet access,
level of expertise in computer use, and current or previ-
ous participation in diabetes self-management education.
Baseline clinical data to be obtained from the medical
record will include:
 date of diagnosis of diabetes
 HbA1c, blood pressure, total cholesterol, HDL
cholesterol and smoking status at time of diagnosis
 presence or absence and date of diagnosis of
complications of diabetes including ischaemic heart
disease, myocardial infarction, congestive cardiac
failure, atrial fibrillation, peripheral vascular disease,
amputation, cerebro-vascular disease, retinopathy,
renal failure and neuropathy
 a list of current medications
 Additional clinical data on height (cm) weight (kg),
systolic and diastolic blood pressure, current
smoking status, and current levels of HbA1c, total
cholesterol and HDL cholesterol will also be
obtained during the baseline visit
Baseline patient reported outcomes include:
 PAID
 HADS
 DTSQ
 EQ-5D
 DMSES
Baseline health economic data includes:
 Clinical data as above
 Health service utilisation in the 12 months prior to
baseline visit.
Follow up data will be collected at 3 and 12 months
with 12 months as the primary outcome point. At follow-
up data will be collected on the clinical and patient
reported outcomes listed above, along with attendance at
alternative self-management education. Demographic data
will only be collected at baseline.
Data on use of health service utilisation will be col-
lected for the past 12 months at baseline, the past
3 months at 3 month follow-up and the past 9 months
at 12 month follow-up. Data on completion of the “9 es-
sential processes” will be collected from the GP record
for the 12 months prior to randomisation and the
12 months after randomisation at the 12 month follow-
up point to avoid triggering behaviour change amongst
the study nurses.
Standard operating procedures (SOPs) will cover every
aspect of data collection and nurses will be trained in
these procedures. Adherence to SOPs will be monitored.
Participants will complete self-reported questionnaires
(demographics, PAID, HADS, DMSES, DTSQ, EQ-5D
and community and social service use) online, prior to
the nurse recording clinical outcomes and taking blood
for HbA1c and lipids. Clinical data will be entered dir-
ectly into the online database by the nurse. Data on util-
isation of primary and secondary health care services
will be extracted from the clinical record by the nurse.
Concealment of allocation, blinding and protection
against bias
Baseline data will be obtained prior to randomisation.
Randomisation will be performed centrally and alloca-
tion will not be revealed to the participants who will
have been informed that the trial is comparing two
forms of web-based education for diabetes (a simple/
straightforward version vs. a more detailed/complicated
version). Practice nurses will be provided with similar
looking booklets for both comparator and intervention
websites. There are potential problems with contamin-
ation (e.g. two members of the same household being
randomised to different interventions with individual
randomisation but cluster randomisation has greater po-
tential to introduce bias by affecting GP behaviour
(which patients they refer to the trial) and patient behav-
iour (participation). We will monitor the extent to which
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contamination occurs by determining the proportion of
participants who had contact with another trial partici-
pant with a different treatment allocation.
The risk of bias in collection of follow-up data will be
minimised by using standardised data collection instru-
ments with participants completing self-assessment ques-
tionnaires before seeing the nurse to record clinical data.
Clinical data will be collected by research nurses who will
be trained to adhere to detailed SOPs developed in collab-
oration with PRIMENT CTU. Follow-up data will be col-
lected by different nurses to those who undertake the
baseline visits and training. Nurses collecting follow-up
data will be blind to allocation. Blood pressure will be re-
corded using automated electronic sphygmanometers.
Adherence and loss to follow-up
Fidelity of the intervention will be promoted through
training practice nurses and provision of detailed SOPs
to guide how nurses introduce participants to the inter-
vention. Use of the intervention and comparator web-
sites will be recorded automatically.
Every effort will be made to promote follow-up which
will be co-ordinated by the trial manager centrally. At
each follow-up point (3 and 12 months) participants will
be sent up to two automated emails containing an em-
bedded hotlink to the follow-up questionnaires. Non-
responders will be sent an additional (third) personalised
email from the trial manager, explaining how important
follow up data are for the study, and the link will also be
resent. After this, participants are sent a letter through
the post, containing both the link and pencil-and-paper
versions of the questionnaires with a stamped addressed
envelope for returning it, in case participants prefer to
complete the questionnaires offline. Finally, the trial
manager will contact the patient by phone to explore
reasons for non-response, encourage response, and if ne-
cessary, ask the patient to complete the PAID verbally
over the phone.
Practice nurses are reminded of the need to offer par-
ticipants follow-up appointments and to complete the
Case Report Form (CRF) for clinical and health eco-
nomic data.
Sample size
We hypothesise that use of the intervention will improve
both PAID scores and HbA1c. The analyses will gain
power through adjustment for baseline levels. We have
back-calculated the relevant effective standard deviations
(SDs) from a previous trial as 0.676 for HbA1c and 10.75
for PAID, substantially lower than the SDs of cross-
sectional measures of around 1.4 and 16 respectively be-
cause of the correlation between baseline and subsequent
measures. We intend to recruit 350 participants; with at-
trition of up to 15 % we anticipate at least 300 patients for
the primary analysis. This will give us 90 % power of de-
tecting at a 5 % significance level a true average difference
in the PAID score of 4.0 and 0.25 % change in HbA1c.
These are both small effect sizes. Since HbA1c and PAID
are joint primary outcomes measuring very different as-
pects of T2DM both will be tested at a 5 % significance
level. Results from both outcomes will be presented side-
by-side in any publication irrespective of their statistical
significance. This follows similar practice in other trials in
this area [21].
Analysis
The analysis will follow a pre-specified analysis plan based
on comparing the groups as randomised (intention-to-
treat). Follow-up HbA1c will be adjusted for initial levels
and other baseline covariates including age, gender, centre,
participation in other self-management programmes, pre-
existing cardiovascular disease and duration of diabetes.
PAID and other outcome measures will be analysed simi-
larly. Sub-group analysis will be undertaken by baseline
glycaemic control and duration of diabetes, treating all
potential effect modifiers as continuous. For the purpose
of presentation, results will be shown for those with good
vs. poor baseline glycaemic control (HbA1c 7.5 % or
greater vs. 7.4 % or less). Missing follow-up data will be
multiply imputed where possible using other outcome
data (e.g. 3 m data when 12 m data are missing) and other
sensitivity analyses investigating the potential for bias
undertaken.
The amount of use the intervention receives (e.g.
number of log-ins) will be further investigated as a po-
tential mediator for efficacy. Using instrumental variable
methods with randomisation as the instrument, an un-
biased estimate of the average causal effect of the inter-
vention on the primary outcomes (HbA1c and PAID)
will be obtained in a subgroup who would use the inter-
vention a certain amount [22].
If contamination (where members of the control group
have access to the active intervention e.g. through a fam-
ily member in the intervention group) does occur it will
be dealt with in the analysis by:
a) Our main (primary) analysis will be a full intention-
to-treat analysis on the whole trial population
b) We will report the extent of any contamination
c) We will undertake a sensitivity analysis using
non-contaminated controls in the control arm only.
However as this loses the benefits of randomisation
we will also
d) Undertake a Complier Average Causal Effect
(CACE) analysis which respects randomisation.
For this CACE analysis we would label
contaminated control participants as potential
non-compliers [23].
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Economic analysis
Incremental cost-effectiveness
The determination of within-trial incremental cost-
effectiveness of facilitated access to HeLP-Diabetes com-
pared to usual care for patients with T2DM will follow
NICE guidance by adopting both a health and personal
social services and a wider public sector resource per-
spective [24, 25]. The components of the analysis are
health outcomes, costs of the active and control inter-
vention, and the potential impact on diabetes care and
complications. QALYs will be calculated using area
under the curve analysis from the baseline, 3- and 12-
month follow-ups, adjusting for baseline levels. Interven-
tion costs will be measured directly. NHS and social care
costs will be calculated from the self-reported usage data
collected from patients and the data extracted from the
electronic medical record by nurses.
Costs of the intervention
Costs of the intervention to the NHS are made up of
two major components: development of the intervention
and facilitation/implementation costs. The resources re-
quired for the development of the intervention will be
monitored during the development process. Once the
intervention has been developed it will need ongoing
maintenance and updating; these costs will be recorded.
The economic evaluation will include the maintenance
and hosting costs, with research costs separated from
treatment costs. Development costs will be considered
sunk costs and not included in the analysis as these
would not be incurred if the intervention were rolled
out in practice.
Facilitated access and implementation costs
Implementation costs will be largely made up of staff
time health professional time, and patient time. A pro-
forma will be constructed so that time spent by the im-
plementation staff in the project can be attributed to the
different stages of the implementation process. The indi-
vidual help given to each patient and health professional
will be collected and coded to each practice, and costed
on the basis of the full economic costs of the staff in-
volved. Estimates of the additional time required from
the general practice staff will be obtained. The costs of
health professional input from the practices will be
based on national average rates using PSSRU (Personal
Social Services Research Unit) estimates. Costs calcu-
lated for the different implementation and facilitated ac-
cess activities will be estimated for each participating
practice and compared to patient activity. The data will
be used to construct models of the potential implemen-
tation costs and population benefits for a “typical” Clin-
ical Commissioning Group and how these costs and
effects may vary with different levels of implementation.
Long term costs
We will estimate the longer term costs associated with
the trial population using the UKPDS model developed
by the University of Oxford [26]. Data on the relevant
parameters will be collected during the trial and their
values used to model and project longer term costs.
Discussion
The problems with external validity of trials, and in par-
ticular, the problem of highly selected trial populations
have been highlighted recently [27]. In this pragmatic
trial we have kept the exclusion criteria to a minimum
with the goal of maximising external validity and ensur-
ing the results generalise to the target population. With
this in mind we have also endeavoured to minimise the
response burden on participants while capturing out-
comes of interest to patients and their clinicians. The
issue of additional work as a result of participating in a
trial is also extremely pertinent to the staff in participat-
ing general practices. English general practice is under
enormous strain [28], and if a practice is struggling to
deliver core services, there may be significant capacity
issues limiting staff ability to adhere to trial protocols.
The results of this trial will add to the evidence base
on different models of supporting self-management of
patients with T2DM, and that on the effectiveness of
web-based programmes for long term conditions. The
results are likely to be of interest to policy makers, clini-
cians and commissioners, particularly in view of the ur-
gent need to increase uptake of self-management
education in people with T2DM.
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